# Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection

> **NCT04438694** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cairo University** · enrollment: 67 (estimated)

## Conditions studied

- COVID19

## Interventions

- **BIOLOGICAL:** Convalescent Plasma
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04438694
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438694, "Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04438694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*